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Abstract
Background: Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET
Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic
and thus susceptible to immune targeting.
Methods: We characterized the effects of BET bromodomain inhibition using JQ1 on PD-L1 and HLA-ABC
expression in two human prostate cell lines, DU145 and PC3. RNA-Seq was performed to assess changes on a
genome-wide level. A cytotoxic T cell killing assay was performed in MC38-OVA cells treated with JQ1 to
demonstrate increased immunogenicity. In vivo experiments in the Myc-Cap model were conducted to show the
effects of JQ1 administration in concert with anti-CTLA-4 checkpoint blockade.
Results: Here, we show that targeting BET bromodomains using the small molecule inhibitor JQ1 decreased PD-L1
expression and mitigated tumor progression in prostate cancer models. Mechanistically, BET bromodomain
inhibition increased MHC I expression and increased the immunogenicity of tumor cells. Transcriptional profiling
showed that BET bromodomain inhibition regulates distinct networks of antigen processing and immune
checkpoint molecules. In murine models, treatment with JQ1 was additive with anti-CTLA-4 immunotherapy,
resulting in an increased CD8/Treg ratio.
Conclusions: BET Bromodomain inhibition can mediate changes in expression at a genome wide level in prostate
cancer cells, resulting in an increased susceptibility to CD8 T cell targeting. These data suggest that combining BET
bromodomain inhibition with immune checkpoint blockade may have clinical activity in prostate cancer patients.
Keywords: Epigenetic, BET, Bromodomain, Cancer immunology, Immunotherapy, Immune checkpoint blockade,
Prostate cancer, CTLA-4, Treg, Immune checkpoint inhibition
Introduction
Prostate cancer is the second leading cause of cancer-
related death in U.S. men [1]. Despite advances in im-
munotherapy, immune checkpoint blockade has yet to
confer significant benefit for patients with prostate can-
cer [2–4]. This resistance to immunotherapy may be due
in part to the fact that prostate cancer is poorly infil-
trated by cytotoxic T-cells as compared to other solid
tumors [4]. Since PD-1 / PD-L1 blockade functions by
blocking the inhibitory interactions between tumor cells
and T-cells, much of its mechanism of action relies on
the presence of a pre-existing anti-tumor T cell response
[5]. The lack of CD8 infiltration in prostate cancer may
be attributable to several factors, including the presence
of suppressive regulatory T-cells (Tregs) [6], and/or
myeloid-derived suppressor cells (MDSCs) that serve to
dampen cytotoxic effects [7]. Additionally, prostate
tumor cells themselves commonly downregulate MHC
Class I expression [8] to evade immune detection.
Recently, epigenetic modulating drugs have emerged as
potential agents to reprogram tumor cells, reversing the
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: cgd2139@cumc.columbia.edu
2Columbia Center for Translational Immunology, Columbia University Medical
Center, New York, NY 10032, USA
6Department of Urology, Columbia University Medical Center, New York, NY
10032, USA
Full list of author information is available at the end of the article
Mao et al. Journal for ImmunoTherapy of Cancer           (2019) 7:277 
https://doi.org/10.1186/s40425-019-0758-y
acquired epigenetic changes that cancer cells accumulate
throughout their evolution and progression [9, 10], including
those that contribute to immune evasion. Of particular inter-
est are epigenetic modifiers targeting bromodomains, protein
domains that recognize acetylated lysine residues such as
those on histone proteins which couple the “reading” of acti-
vating marks to the transcription machinery [11, 12]. The in-
hibition of BRD4, a member of the Bromodomain and
ExtraTerminal (BET) family of bromodomain-containing
proteins, was recently shown to reduce levels of Androgen
Receptor (AR) driven target genes in prostate cancer, and re-
duce tumor burden in murine models [12]. Due to its role as
a transcriptional regulator, it is possible that BRD4 recruit-
ment mediates not only oncogenic drivers like AR [13] and
MYC [14], but also plays a role in regulating immune net-
works as well.
To understand the effects of BET Bromodomain inhib-
ition on the immunogenicity of prostate cancer, we per-
formed a series of studies examining the effects of
inhibition on the levels of immunologically relevant mol-
ecules. In addition, we tested whether BRD4 inhibition
rendered tumor cells more susceptible to CD8-mediated
lysis, both in vitro and in vivo.
Results
BET Bromodomain inhibition reduces PD-L1 expression
To investigate the effects of epigenetic drugs on the im-
munogenicity of prostate cancer, we tested a panel of
twelve different small-molecule inhibitors – these agents
were selected to target a variety of epigenetic mechanisms
including DNA methylation, histone deacetylation, and
bromodomains (Additional file 1: Table S1). The primary
readout for these studies was PD-L1 expression, since the
PD-1 / PD-L1 interaction has emerged as a major immuno-
suppressive mechanism in several tumor types [15–17]. To
model advanced prostate cancer, we used the human pros-
tate cancer cell lines DU145 and PC3, both of which are
negative for androgen receptor signaling [18]. As shown in
Fig. 1a, the BET bromodomain BRD4 inhibitor JQ1 was the
only small molecule inhibitor tested that suppressed PD-L1
expression significantly. We then chose two doses of JQ1,
0.1 μM and 1 μM for further testing based the ability of
these dose levels to down-regulate PD-L1 with relatively
minimal effects on proliferation (Additional file 2: Figure
S1). Since PD-L1 expression in tumors is likely driven by
IFN-γ in the tumor microenvironment (TME) [19, 20], we
next tested whether bromodomain inhibition could inhibit
IFN-γ mediated PD-L1 up-regulation. This was indeed the
case, as JQ1 suppressed IFN-γ driven PD-L1 expression in
both PC3 and DU145 cells in a dose-dependent manner
(Fig. 1b-e). To support the specificity of this effect, we uti-
lized a second small molecule inhibitor (RVX208); this
agent inhibits the second bromodomain (BD2) of BET
proteins with 170-fold more specificity than the first
bromodomain (BD1) in targeted proteins [21]. RVX208
was comparable in activity to JQ1 in its ability to suppress
PD-L1 expression in PC3 cells (Additional file 3: Figure
S2A-B). Since BET bromodomains act at the transcriptional
level [22], we quantified mRNA levels of CD274 (PD-L1)
after drug exposure, and found that JQ1 reduced mRNA
levels of CD274 in a dose-dependent manner (Fig. 1f-g).
Taken together, these data show that BET bromodomain
inhibition decreases PD-L1 expression in prostate cancer
cells at both the protein and message level.
BET Bromodomain inhibition increases MHC I expression
In addition to PD-L1, a number of immune molecules
are important in CD8 T cell mediated anti-tumor effects.
In particular, Class I MHC is required for CD8 T cell
antigen recognition and like PD-L1, MHC expression is
up-regulated by pro-inflammatory IFN-γ signaling [23].
If BET Bromodomain inhibition resulted in a global
down-regulation of immune-related molecules (such as
Class I MHC), it could be that the anti-tumor effects
mediated by PD-L1 down-regulation would be attenu-
ated by down-regulation of MHC. This was not the case
- in the presence of IFN-γ, JQ1 exposure resulted in a
further increase in Class I MHC expression (Fig. 2a-d).
As the antibody used in these studies recognizes all 3
human HLA alleles of Class I, we next used qPCR to de-
termine which specific alleles were involved. Interest-
ingly, BET Bromodomain inhibition preferentially
increased HLA-A and possibly HLA-B expression, while
simultaneously mediating a decrease in HLA-C expres-
sion (Fig. 2e-g). These data suggest that the immune ef-
fects of BET bromodomain inhibition may be complex
but highlight increased CD8 T cell recognition as one
possible outcome.
BET Bromodomain inhibition augments susceptibility to
CD8 T cell-mediated cytotoxicity
To test whether PD-L1 down-regulation and MHC Class
I up-regulation potentiates CD8 T-cell mediated lysis,
we employed an antigen-specific model system. For
these studies, we focused on MC38-OVA, a murine
colon cancer line that expresses the OVA peptide as a
model antigen – potentially mimicking a mutation asso-
ciated neoantigen (MANA) [24]. These cells express
moderate PD-L1 levels at baseline, expression is aug-
mented by IFN-γ, and like the human prostate cancer
cells above, JQ1 was able to significantly decrease PD-L1
expression and increase expression of murine Class I
(Additional file 4: Figure S3 A-D). For CD8 killing, we
used transgenic OT-1 T cells, these cells recognize the
OVA peptide SIINFEKL in the context of H-2Kb [25].
As expected, OT-1 T cells lysed OVA-expressing target
cells, with increased killing at increased effector to target
ratios (Fig. 3a). Treating target cells with JQ1 increased
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CD8-mediated tumor cell lysis; this was more pro-
nounced at increased doses. To rule out the possibility
that JQ1 itself mediates MC38 tumor cell lysis, we re-
peated these studies in the absence of antigen-specific
CD8 T cells; as shown in Fig. 3b JQ1 treatment alone
mediated only a moderate, dose-independent increase in
baseline lysis. To test whether JQ1 treatment also results
in increased immunogenicity in vivo, we treated mice
with implanted MC38OVA. Tumors harvested from JQ1
treated mice showed a trend towards decreased PD-L1
expression (Fig. 3c). Additionally, in vivo treatment with
JQ1 led to an increase of OVA-specific CD8 T cells (Fig.
3d) as assessed by OVA tetramer staining.
BET Bromodomain inhibition modulates distinct networks
of immune-related genes
Given the observed increase in MHC Class I and de-
crease in PD-L1 expression, we hypothesized that BRD4
inhibition might modulate expression of additional im-
munologically related transcripts. To gain a better un-
derstanding of these effects on a genome-wide level, we
used RNA sequencing to profile DU145 cells treated
with JQ1 and IFN-γ. We focused downstream analyses
on genes whose expression was modulated by IFN-γ
treatment and sought to determine which of the IFN-γ
modulated transcripts were further modulated by BET
bromodomain inhibition. These data are shown in
Fig. 4a; as one example, IRF7, a transcription factor
which is responsible for transcription of Interferon Stim-
ulated Genes (ISGs) [26], was slightly upregulated by
IFN-γ, with expression further increased in a dose-
dependent manner through BET bromodomain inhib-
ition. Other immune genes further upregulated by BET
bromodomain inhibition over IFN-γ include TNFSF9 (4-
1BBL) and TRIM36, suggesting increased cytotoxic cost-
imulatory ligand expression [27] and potentially im-
proved Class I antigen processing [28]. SOCS1, a
negative regulator of IFN-γ signaling [29], was also up-
regulated by BET bromodomain inhibition, possibly as a
response to the increase in proinflammatory gene ex-
pression (Fig. 4a).
Gene set enrichment analysis (GSEA) on the top 20
upregulated and downregulated genes in the subset
above (IFN-γ modulated transcripts that are further
modulated by BET bromodomain inhibition) using the
Reactome database [30, 31] revealed that the top 20
most upregulated genes were enriched for antigen pres-
entation and TLR signaling pathways (Fig. 4b), whereas
the top 20 most downregulated genes were associated
with cytokine and growth factor signaling pathways (Fig.
4c). Of the 2388 genes whose expression was modulated
by IFN-γ, BET Bromodomain inhibition further altered
the expression of 1847 genes within that subset (Fig. 4d),
confirming the broad immunological target spectrum of
BET bromodomain inhibition. We next interrogated a
selected set of immune-related genes commonly impli-
cated in the anti-tumor response as well as antigen pro-
cessing and presentation [32]. Consistent with the data
in Fig. 2, these data confirmed that MHC Class I HLA-A
and HLA-B transcripts were up-regulated by BET bro-
modomain inhibition; interestingly the opposite trend
was noted for Class II (HLA-DPA1, HLA-DR) expres-
sion (Fig. 4e). BET bromodomain inhibition also down-
modulated expression of the A2A receptor (ADORA2A);
this receptor and others in the extracellular adenosine
pathway may play a role in maintaining a suppressive
tumor microenvironment [33]. We next performed cor-
relation analysis to determine which immune-relevant
transcripts were coordinately regulated. As shown in Fig.
4f, two distinct clusters of immune genes were observed,
with one containing HLA and other genes related to
antigen processing and presentation, and a second con-
taining suppressive molecules like ADORA2A and
ENTPD1 (CD39) (Fig. 4f). Network analysis of these data
(Fig. 4g) showed that CD274 (PD-L1) and PDCD1LG2
(PD-L2) clustered with Class II genes, whereas Class I
genes formed a separate node (Fig. 4g). Taken together,
these data confirm the concept that BET bromodomain
inhibition modulates the expression of a number of im-
munologically relevant transcripts and highlights the
complexity of this regulation in that neither monotonic
up-regulation nor down-regulation was observed.
BET Bromodomain inhibition augments antitumor
immunity and increases tumor infiltration
To quantify the in vivo effects of BET bromodomain in-
hibition on prostate cancer growth, we used the syngen-
eic murine Myc-Cap model [34] . Similar to DU145,
PC3, and MC38OVA, in vitro treatment of Myc-Cap
cells with JQ1 reduces PD-L1 expression and increases
(See figure on previous page.)
Fig. 1 BET Bromodomain Inhibition Downregulates PD-L1 Expression in Prostate Cancer. a Relative PD-L1 MFI (normalized to DMSO control) in
DU145 cells treated with indicated agents, gated on live cells. N = 1 sample / iteration, repeated × 3. b Representative histograms of PD-L1
expression in DU145 cells incubated with JQ1 and/or IFNγ gated on live cells. c Summary flow cytometry data for B, N = 1 sample / iteration,
repeated × 8. d PD-L1 expression in PC3 cells incubated with JQ1 and/or IFNγ, gated on live cells. e Summary flow cytometry data for D, N = 1
sample / iteration, repeated × 8. f PD-L1 (CD274) mRNA levels in DU145. Fold-change normalized to 18 s and to control (DMSO) treatment. N = 3
/ group, repeated × 2. g PD-L1 (CD274) mRNA levels in PC3. Normalized to control (DMSO). N = 3 / group, repeated × 2. * p < 0.05, **p < 0.01, ***
p < 0.001, ****p < 0.0001. Error bars = standard deviation
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Fig. 2 BET Bromodomain Inhibition increases MHC I Expression in Prostate Cancer. a Representative histograms of HLA-ABC expression on DU145
cells treated with JQ1 and/or IFNγ gated on live cells. b Summary flow cytometry data for A (normalized to DMSO control). n = 1 sample /
iteration, repeated × 8. c Representative histograms of HLA-ABC expression in PC3 cells incubated with JQ1 and/or IFNγ gated on live cells. d
Summary flow cytometry data for C (normalized to DMSO control). n = 1 sample / iteration, repeated × 8. e HLA-A mRNA levels in DU145. Fold-
change normalized to 18 s and then normalized to control (DMSO) treatment. n = 3 / group, repeated × 2. f HLA-B mRNA levels in DU145. Fold-
change normalized to 18 s and then normalized to control (DMSO) treatment. n = 3 / group, repeated × 2. g HLA-C mRNA levels in DU145 fold-
change normalized to 18 s and then normalized to control (DMSO) treatment. n = 3 / group, repeated × 2. * p < 0.05, **p < 0.01, *** p < 0.001,
****p < 0.0001. Error bars = standard deviation
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expression of the MHC Class I molecule H2Kq. (Add-
itional file 5: Figure S4). This model mimics the molecu-
lar properties of some human prostate cancers in that it
exhibits AR amplification and overexpresses c-myc [34].
Previous work in our lab showed that anti-PD-1 treat-
ment is ineffective in this model, and that an anti-
CTLA-4 antibody of the isotype IgG2a has pre-clinical
activity [35]. To model therapy for advanced prostate
cancer, we treated robustly established tumors (≈ 450
mm3) with combination therapy using JQ1 and CTLA4
IgG2a. Consistent with our prior studies, anti-CTLA-4
resulted in significant tumor growth inhibition. BET bro-
modomain inhibition as a monotherapy was relatively
ineffective; however combined treated showed a trend
towards increased anti-tumor activity as compared to ei-
ther treatment alone early in treatment (Fig. 5a-b) as
well as a potential survival benefit (Fig. 5c-d). Animals
treated with JQ1+ α-CTLA-4 had a 12.2% longer median
survival than those treated with α-CTLA-4 alone (46
versus 41 days respectively), although that difference was
not statistically significant. We next investigated im-
mune correlates associated with combined treatment. α-
CTLA-4 (IgG2a) increased CD8 infiltration (Fig. 5e),
while decreasing the overall number of Tregs in the tu-
mors (Fig. 5f). Clinically, an increased CD8:Treg ratio
has been associated with improved outcome in a number
of solid tumors [36, 37]; here, combined JQ1 + αCTLA-4
treatment showed a significantly increased CD8:Treg ra-
tio as compared with α-CTLA-4 alone, and this in-
creased ratio correlated with treatment effect (Fig. 5g).
Intratumoral CD8 T cells from mice treated with the
combination regimen showed a trend towards increased
effector cytokine secretion (Fig. 5h-j). These in vivo data
demonstrate a potential additive effect between BET
Bromodomain and anti-CTLA-4, correlated primarily
with an increased CD8:Treg ratio in the tumor. Further
in vivo experiments with DU145 and PC3 xenografts
confirmed the trends in PD-L1 and HLA-ABC expres-
sion seen in vitro. Ex vivo analysis of DU145 and PC3
tumors treated with JQ1 showed a trend towards
Fig. 3 BET Bromodomain Inhibition Augments Susceptibility to CD8 T Cell-Mediated Cytotoxicity. a Specific lysis of JQ1 pretreated MC38OVA cells
by OT-I CD8 cells. Specific lysis calculated as (% Lysis - %Nonspecific Lysis) / (% Maximum lysis - % nonspecific lysis). Significance compared to
DMSO group. N = 3 wells / iteration, repeated × 3. b Percent specific lysis of pretreated MC38OVA cells in the absence of OT-I CD8 cells.
Significance calculated using Tukey’s multiple comparisons test through 2-way Repeated Measures ANOVA . * p < 0.05, **p < 0.01, *** p < 0.001,
****p < 0.0001. Error bars = standard deviation. c Summary of flow cytometry data for PD-L1 staining in ex-vivo MC38OVA tumors, gated on Live
CD45− cells. N = 5 mice / iteration, repeated × 3. d Summary of flow cytometry data for OVA Tetramer staining in ex-vivo MC38OVA tumors gated
on Live CD45+TCRb+CD4−CD8+ cells. N = 5 mice / iteration, repeated × 3
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decreased PD-L1 expression (Additional file 7: Figure
S6A) and increased HLA-ABC expression (Additional
file 7: Figure S6B), similar to the effects seen in treating
DU145 and PC3 cells in vitro (Figs. 1-2).
Discussion
Prostate cancer has remained relatively insensitive to im-
mune checkpoint blockade [38], and this can be attrib-
uted to a number of factors, including a relatively low
tumor mutation burden (TMB) [39], and a sparse infil-
tration of lymphocytes [40]. We found that inhibition of
the BET Bromodomain BRD4 can reduce PD-L1 expres-
sion (Figs. 1b-e) and increase MHC Class I expression
(Figs. 2a-d) on the surface of prostate tumor cells. These
data are consistent with prior data using ovarian cancer
cells [41]; here we extend those data significantly by
demonstrating a contemporaneous increase in Class I
MHC expression. Additionally, these conclusions were
further borne out in xenograft models of DU145 and
PC3, where JQ1 treatment decreased PD-L1 expression
and increased Class I expression. (Additional file 7: Fig-
ureS6). In vivo CTL analyses demonstrated that these
changes were immunologically relevant, as JQ1 pre-
treatment resulted in increased susceptibility of tumor
cells to antigen-specific CD8-mediated lysis (Fig. 3a-b).
These trends were further corroborated in vivo of JQ1
treated MC38 tumors, in which PD-L1 expression was
decreased, and there was a significant increase in OVA-
specific CD8 infiltrate into the tumor (Fig. 3c-d).
Fig. 4 BET Bromodomain Inhibition Modulates Distinct Networks of
Immune-Related Genes. a Top 20 upregulated and downregulated
transcripts significantly altered by IFNγ significantly further
modulated in the presence of 1uM JQ1 in DU145 cells. Scale
represents log transformed FPKMs + 0.1, data are row normalized. b
Gene set enrichment analysis (GSEA) using the Reactome database
in EnrichR for top 20 genes whose expression is significantly altered
by IFNγ and whose expression is upregulated by incubation with
1uM JQ1 in DU145 cells. Colors represent ranking based on
combined enrichment score (a value calculated through multiplying
log p-value and z-score), with highest enrichment scores in brighter
shades. c GSEA using the Reactome database in EnrichR for top 20
genes whose expression is significantly altered by IFNγ and whose
expression is downregulated by addition of 1uM JQ1 in DU145 cells.
Colors represent ranking based on combined enrichment score, with
highest enrichment scores in brighter shades. d Genes in DU145
cells significantly downregulated or upregulated with IFN-γ
treatment whose expression is further modulated with JQ1
treatment. e Expression of immune-related genes, including Class I,
Class II, and checkpoints, in DU145 cells across treatment conditions.
Scale represents log transformed FPKMs + 0.1, data are row
normalized. f Correlation matrix of immune-related genes in DU145
cells across treatment conditions. g Networks of immune-related
genes, including Class I, Class II, and checkpoints, altered by JQ1
treatment. Lines indicate strength of connections between two
genes, and size of node represents relative importance of gene in
the network.p < 0.05 for all significantly differentially expressed
transcripts. N = 3/group, repeated × 1
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On a broader level, our RNA-sequencing data using
human prostate cancer cell lines showed that BET bro-
modomain inhibition alters the expression of a number
of immune-related genes, and that JQ1 treatment further
upregulates antigen presentation pathways initiated by
IFN-γ treatment, while potentially decreasing signaling
through certain growth factor pathways (Fig. 4). For ex-
ample, TAF9, a subunit of the Transcription Factor IID
(TFIID) required for initiation of transcription by RNA
Polymerase II [32], is significantly upregulated by JQ1
(Fig. 4a, Additional file 5: Figure S4), but most signifi-
cantly at the higher dose of JQ1. TAF9 associates with
CIITA, the MHC Class II transactivator [42], a complex
responsible for upregulating Class I genes upon IFN-γ
stimulation [43].
Interestingly, we found that JQ1 appears to differen-
tially modulate expression of Class I MHC alleles. A
similar phenomenon was previously shown to occur in
the context of cytokine stimulation [44, 45]; in those
studies differential expression was modulated by differ-
ential affinity of the NF-kB subunit RelA for the HLA-A
and B promoter over HLA-C [45]. That pattern of ex-
pression is similar to what we found when bromodo-
main inhibition was added to IFN-γ treated cells,
suggesting a potential common affinity based mechan-
ism. It is also possible that JQ1 inhibits the transcription
of one of the inhibitors of RelA/NF-kB activation, thus
enhancing its ability to bind selectively to HLA-A and B
to increase both mRNA and protein levels.
Immunologically, we further found that TRIM36, an
E3 ubiquitin-protein ligase, was upregulated in a
dose-dependent manner by BET Bromodomain inhib-
ition combined with IFN-γ; increased TRIM36 expres-
sion has been correlated with inhibition of prostate
cancer proliferation and cell-cycle progression through
inhibition of the MAPK/ERK pathway [46]. TRIM36
is also involved in antigen processing [28]. Consistent
with our data showing that PD-L1 is decreased with
JQ1 treatment, other groups have shown that BRD4
binds directly to the PD-L1 promoter to mediate its
transcription [41, 47, 48] such that inhibition of
BRD4 would decrease the mRNA and protein levels
of PD-L1. These genome-wide changes suggest that
BET bromodomain inhibition can enhance the im-
munogenicity of prostate cancer while also acting on
the tumor cells to inhibit their growth.
Taken together, these data demonstrate the activity of
anti-CTLA-4 and BET bromodomain inhibition in a mur-
ine prostate cancer model. Previous work in a murine
lymphoma model showed a similar decrease in PD-L1
upon treatment with JQ1 in vitro, and an additive effect of
JQ1 and anti-PD-1 in prolonging survival in vivo [48].
Despite the differences between the lymphoma model and
the Myc-Cap model, which is unresponsive to anti-PD-1
[35], the trends seen in PD-L1 decrease and improved
tumor control are consistent. Our lab previously demon-
strated the activity of anti-CTLA-4 in the Myc-Cap model
[35] and showed that CTLA-4 immunotherapy signifi-
cantly increased the production IFN-γ by CD8 and CD4
tumor-infiltrating T cells [35]. Mechanistically, the trend
towards increased anti-tumor activity of combination
treatment correlated with an increased CD8:Treg ratio
and a trend toward increased intratumoral CD8 effector
function. Although anti-CTLA-4 is not currently FDA-
approved for the treatment of advanced prostate cancer, a
randomized Phase III trial [49] showed a trend towards in-
creased survival, suggesting that this agent may have some
clinical activity. The data here suggest that activity could
be augmented by BET bromodomain inhibition, leading
to improved antitumor responses in the clinic.
Materials and methods
Cell culture
Human prostate cancer cell lines PC3 and DU145 were
obtained from ATCC (Manassas, VA, USA) and grown
in a monolayer under standard culture conditions, 5%
(See figure on previous page.)
Fig. 5 BET Bromodomain Inhibition Augments Antitumor Immunity and Increases Tumor Infiltration. a Volume of MycCap tumors treated as
indicated, rx initiated d28 post-implatation. Each line represents an individual tumor. Arrows indicate start of treatment on d26. N = 10/group,
repeated × 2. b Summary data of mean tumor growth for A. N = 10/group, repeated × 2. Error bars represent S.E.M. Arrows indicate start of
treatment on d26. c Mean survival of animals with MycCap tumors in indicated treatment groups. N = 10/ group, repeated × 2. Lines indicate
mean survival. Error bars represent S.E.M. d Survival of animals with MycCap tumors in indicated treatment groups. N = 10/group, repeated × 2.
Lines indicate percent survival. Significance calculated using Log-rank (Mantel-Cox) test. **p = 0.0046 for Vehicle vs. JQ1 + aCTLA-4, *p = 0.0278 for
Vehicle vs. aCTLA-4. No other comparisons between growth curves were significant. e Live CD45+TCRb+CD4−CD8+ (CD8) cells /mg tumor in
MycCap tumors from animals treated as indicated. N = 10/group, repeated × 2. f Live CD45+TCRb+CD4+CD8−FoxP3+ (Treg) / mg tumor in MycCap
tumors from animals in indicated treatment groups. N = 10/group, repeated × 2. g Ratio of live CD45+TCRb+CD4−CD8+ (CD8) cells to
CD45+TCRb+CD4+CD8−FoxP3+ (Treg) cells in MycCap tumors from treatment groups indicated. N = 10/group, repeated × 2. h TNFα and
Granzyme B secretion from stimulated live CD45+TCRb+CD4−CD8+ (CD8) cells in MycCap tumors from mice in treatment groups as indicated.
Gates were set based on non-stimulated CD8 controls. i Summary of mean fluorescence intensity (MFI) of Granzyme B staining in stimulated live
CD45+TCRb+CD4−CD8+ (CD8) cells in MycCap tumors from mice in treatment groups as indicated. N = 10 mice/group, repeated × 2. j Summary
of mean fluorescence intensity (MFI) of TNFα staining in stimulated live CD45+TCRb+CD4−CD8+ (CD8) cells in MycCap tumors from mice in
treatment groups as indicated. N = 10 mice/group, repeated × 2. * p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001. P values were calculated
through one-way ANOVA. Error bars shown represent S.E.M
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CO2 in a 37 °C incubator, in RPMI 1640 (Corning,
Corning, New York, USA) supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin. Cell iden-
tity was confirmed by short tandem repeat (STR) typing.
Cells were tested for mycoplasma by PCR. For flow cy-
tometry studies, cells were plated at a density of ~ 5,000/
cm2 into 6-well tissue culture plates or T-175 tissue cul-
ture flasks (for qPCR and RNA-Seq) and were allowed
to adhere for 24 h. After 24 h, cells were treated with ei-
ther 1 μM or 0.1 μM JQ1 (S7110, Selleckchem, Houston,
TX, USA) and/or 100 units/mL of human interferon
gamma (IFN-γ) (300–02, Pepro Tech, Rocky Hill, Con-
necticut, USA) for 48 h prior to harvest.
Epigenetic drug screen
DU145 cells were plated as described above, and allowed
to adhere for 24 h. After 24 h, cells were treated with ei-
ther 100 units/mL of human interferon gamma (IFN-γ)
(300–02, Pepro Tech, Rocky Hill, Connecticut, USA), or
one of the following drugs at a concentration at approxi-
mately the published IC50 on the manufacturer’s prod-
uct page: 0.01 μM GSK591 (S8111, Selleckchem), 0.1 μM
GSK484 (17,488, Cayman Chemicals, Michigan, USA),
0.1 μM MS049 (18,348, Cayman Chemicals), 0.1 μM
SGC707 (S7832, Selleckchem), 0.01 μM GSK343 (S7164,
Selleckchem), 0.1 μM LLY-507 (S7575, Selleckchem),
0.1 μM A-196 (S7983, Selleckchem), 0.1 μM JQ1 (S7110,
Selleckchem), 0.1 μM NVS-1 (5744, Tocris Biosciences,
Bristol, UK), 0.1 μM LP-99 (17,661, Cayman Chemicals),
0.1 μM Entinostat (S1053, Selleckchem), or 0.1 μM 5-
Azacytidine (S1782, Selleckchem) for 48 h prior to har-
vest. Cells were stained with Brilliant Violet 421™
(BV421) mouse anti-human PD-L1 1:50 (CD274, Clone
29E.2A3, BioLegend, San Diego, CA, USA) and eFluor™
780 fixable viability dye 1:10000 (65,086,514, Invitrogen,
Waltham, MA, USA) using the flow cytometry process
detailed below.
Flow Cytometry
PC3 and DU145 cells were stained with Brilliant Violet
421™ (BV421) mouse anti-human PD-L1 1:50 (CD274,
Clone 29E.2A3, BioLegend, San Diego, CA, USA), PE
mouse anti-human HLA-A,B,C 1:100 (Clone W6/32, Bio-
Legend, San Diego, CA, USA), and eFluor™ 780 fixable via-
bility dye 1:10000 (65,086,514, Invitrogen, Waltham, MA,
USA). Staining was performed in PBS for 20min at room
temperature. Cells were analyzed using a BD FACSCelesta
(Becton Dickinson, Franklin Lakes, New Jersey, USA) and
FlowJo software (Tree Star, Ashland, Oregon, USA). The
relative mean fluorescence intensity (MFI) was calculated
as the MFI of each experimental sample/MFI of vehicle
(DMSO) control.
Quantitative real-time PCR
PC3 and DU145 cells were cultured and treated as indi-
cated above. Total RNA was extracted using TRIzol re-
agent (15596–026, Invitrogen) followed by chloroform
extraction as previously described [50]. cDNA was pre-
pared from total RNA using the RNA to cDNA EcoDry
Premix (Clontech, Mountain View, CA). qPCR detec-
tion of human CD274, HLA-A, HLA-B, and HLA-C
were performed with TaqMan gene expression assays
(Applied Biosystems, Foster City, CA, USA) according
to protocol provided by manufacturer using TaqMan
Universal Master Mix II no UNG (4,440,040, Applied
Biosystems, Foster City, CA, USA) and analyzed on the
ABI Viia 7 (Applied Biosystems). The ΔΔ CT method
was used to quantify relative mRNA expression. Ex-
pression of each target gene was normalized to that of
the reference gene 18S. qPCR wells were plated in trip-
licate and each assay was repeated at least 3 times.
CTL assays
6–8 week old female OT-1 mice (003831, Jackson La-
boratories, Farmington, CT, USA) were allowed to accli-
mate for 2 weeks after arrival to the facility. Animals
were housed in specific pathogen-free facilities accre-
dited by the American Association for the Accreditation
of Laboratory Animal Care (AAALAC) with protocols
approved by the Animal Care and Use Committee of the
Columbia University School of Medicine (New York,
NY). They were then sacrificed, and spleen and lymph
nodes were excised. Following manual dissociation, cells
were counted and resuspended at a concentration of 5 ×
106 cells/mL with 10 ng/mL of OVA SIINFEKL peptide
(AS-60193-1, AnaSpec, Freemont, CA, USA), and plated
at a density of about 2.5 × 106 cells/cm2 in a tissue cul-
ture multi-well plate. After 48 h, cells were scraped,
washed once with sterile PBS, and then isolated using
Ficoll-Paque® PLUS (17–1440-03, GE Healthcare, Chi-
cago, IL) according to manufacturer’s protocol in order
to remove dead cells. These cells were then resuspended
in media containing 10 ng/mL of murine IL-2 (212–12,
PeproTech) and plated at 2.5 × 106 cells/cm2 in a tissue
culture multi-well plate to expand for an additional 24 h.
OT1 CD8 cells were isolated using the mouse CD8a+ T
Cell Isolation Kit (130–104-075, Miltenyi Biotec, Ber-
gisch Gladbach, Germany) according to protocol pro-
vided by manufacturer. Lytic assays were performed
using MC38-OVA cells plated in 6-well tissue culture
plates at a starting density of ~ 5000/cm2 in DMEM
(Corning, Corning, New York, USA) containing 10%
fetal bovine serum and 1% penicillin/streptomycin under
standard culture conditions, 5% CO2 in a 37 °C incuba-
tor. After 24 h, cells were treated with either 1 μM or
0.1 μM JQ1 (S7110, Selleckchem, Houston, TX, USA)
and/or 20 ng/mL of murine interferon gamma (IFN-γ)
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(315–05, Pepro Tech, Rocky Hill, Connecticut, USA) for
48 h. Cells were then harvested by exposing cells to
Trypsin-EDTA 0.05% (25,300,054, Gibco, Grand Island,
New York, USA) for 1 min. The MC-38 OVA cells were
then labeled with 20 μM PKH26 Red Fluorescent Cell
Linker Kit (MINI26, Sigma-Aldrich, Saint Louis, MO,
USA) according to protocol provided by manufacturer.
The cells were washed thoroughly to remove residual
PKH26 dye, and then pulsed with 10 ng/mL of OVA
peptide (AnaSpec) for 4 h. Cells were then harvested by
exposing cells to Trypsin as before, and then washed to
remove residual peptide. 3 × 104 target MC38-OVA cells
were placed each well of a 6-well culture plate and
allowed to adhere for 4 h, and OT1 CD8s activated as
detailed above were then added to each well at the indi-
cated Effector: Target ratios. After 12 h, cells were har-
vested and placed on ice to prevent additional killing.
Cells were stained with eFluor™ 780 fixable viability dye
1:10000 (Invitrogen) to discern cell death on ice for 30
min, and were immediately analyzed using a BD FACS-
Celesta (Becton Dickinson) and FlowJo software (Tree
Star). PKH26+Viability Dyehi cells were considered lysed
MC-38 OVA. Each treatment condition was plated in
triplicate, and the assay was repeated twice.
RNA-sequencing
RNA sequencing and analysis of treated DU145 and PC3
cells was performed by the JP Sulzberger Columbia Gen-
ome Center Core Facility. Total RNA was extracted
from cells treated as above using Trizol Reagent
(15596–026, Invitrogen). RNA purity was assessed en-
sure RIN was greater than 8. mRNA was enriched from
total RNA (approx.. 150 ng/sample) using poly-A pull-
down, and subsequently the Illumina TruSeq RNA prep
kit (Illumina, San Diego, CA, USA) was used for library
preparation. Libraries were sequenced using the Illumina
HiSeq2500 (Illumina) with multiplexed samples in each
line, which yields targeted number of single-end 100 bp
reads for each sample, with an average of 30 million
reads per sample. RTA (Illumina) was used for base call-
ing, and bcl2fastq2 (version 2.17) was used for convert-
ing BCL to fastq format, coupled with adaptor trimming.
Reads were mapped to the reference genome (Human:
NCBI/build37.2; Mouse: UCSC/mm10) using STAR
(2.5.2b) and featureCounts(v1.5.0-p3). Differential ex-
pression between groups were assessed using the R
package DEseq, which uses a negative binomial distribu-
tion that models the number reads from RNA-seq ex-
periments and test for differential expression. Three
samples per condition per cell line were submitted for
sequencing. Fragments per kilobase of transcript (FPKM)
were used for downstream analysis including heatmaps
and correlation matrix analysis. Spearman’s correlation
was used to calculate pairwise comparisons for the im-
mune genes and network analysis.
Gene set enrichment analysis
Genes that were significantly differentially expressed
(P < 0.05) between the DMSO treated group and the
IFN-γ treated group were compared to the list of genes
that were significantly differentially expressed between
the IFN-γ treated group and IFN-γ + 1 μM JQ1 treated
group. Genes that appeared on both lists were then sep-
arated into those that were upregulated or downregu-
lated based on positive or negative fold-change in the
DEseq analysis. The magnitude of the fold-change was
used to discern genes that were the most upregulated or
downregulated. The list of the 20 most upregulated and
downregulated genes were input into EnrichR [30, 31] to
assess changes in Reactome pathways. The significance
of pathways were ranked using the combined score,
which is a combination of the p-value and z-score calcu-
lated as previously described [30].
In-vivo tumor models
Myc-Cap cells were obtained from ATCC (Manassas,
VA, USA) and grown in a monolayer under standard
culture conditions, 5% CO2 in a 37 °C incubator, in
DMEM 1640 (Corning, Corning, New York, USA) sup-
plemented with 10% fetal bovine serum and 1% penicil-
lin/streptomycin. 1 × 106 Myc-Cap cells were implanted
subcutaneously into 8–10 week old male FVB/NJ mice
(001800, Jackson Laboratories, Farmington, CT, USA) in
the right flank as previously described [51]. Animals
were housed in specific pathogen-free facilities accre-
dited by the American Association for the Accreditation
of Laboratory Animal Care (AAALAC) with protocols
approved by the Animal Care and Use Committee of the
Columbia University School of Medicine (New York,
NY). Tumor dimensions were measured with an elec-
tronic caliper every 2–3 days as indicated. Overall tumor
volumes were calculated as 0.5 × longest diameter ×
shortest diameter2. Mice were randomized into treat-
ment groups as indicated on day 26 when tumors
reached approximately 450 mm3, receiving either Vehicle
(5% DMSO in 10% 2-hydroxypropyl-β-cyclodextrin) +
IgG2a isotype control, 50 mg/kg JQ1 via intraperitoneal
(IP) injection daily, 10 mg/kg aCTLA-4 (IgG2a) IP every
other day for 3 doses, or both. Mice were euthanized
once tumors exceeded 2 cm in either dimension, or
when tumors became ulcerated or mice showed signs of
dehydration/illness. Anti–CTLA-4 and the correspond-
ing IgG2a isotype control was a generous gift from Dr.
Alan Korman and Dr. Mark Selby, provided under an
MTA with Bristol-Myers Squibb (Redwood City, CA).
MC38OVA cells were a generous gift from Dr. Mark
Smyth (Melbourne, Australia) and grown in a monolayer
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under standard culture conditions, 5% CO2 in a 37 °C
incubator, in DMEM 1640 (Corning, Corning, New
York, USA) supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin. 5 × 105 MC38OVA cells
were implanted subcutaneously into 8–10 week old male
C57/BL6 mice (000664, Jackson Laboratories, Farming-
ton, CT, USA) in the right flank as previously described
[51]. Animals were housed in specific pathogen-free fa-
cilities accredited by the American Association for the
Accreditation of Laboratory Animal Care (AAALAC)
with protocols approved by the Animal Care and Use
Committee of the Columbia University School of Medi-
cine (New York, NY). Tumor dimensions were measured
with an electronic caliper every 2–3 days as indicated.
Overall tumor volumes were calculated as 0.5 × longest
diameter × shortest diameter2. Mice were randomized
into treatment groups as indicated on day 11 when tu-
mors reached approximately 150 mm3, receiving either
Vehicle (5% DMSO in 10% 2-hydroxypropyl-β-cyclodex-
trin) or 50 mg/kg JQ1 via intraperitoneal (IP) injection
daily. Mice were sacrificed on d17 for ex vivo flow cy-
tometry analysis of tumor PD-L1 (Clone 10F.9G2, Bio-
Legend) expression as well as OVA-specific CD8 TIL
using OVA Tetramer staining (MBL International, Wo-
burn, MA, USA).
DU145 and PC3 cells were obtained from ATCC (Ma-
nassas, VA, USA) and grown in a monolayer under stand-
ard culture conditions, 5% CO2 in a 37 °C incubator, in
RPMI 1640 (Corning, Corning, New York, USA) supple-
mented with 10% fetal bovine serum and 1% penicillin/
streptomycin. 3 × 106 DU145 or PC3 cells were implanted
subcutaneously into 8–10week old male J:Nu mice
(007850, Jackson Laboratories, Farmington, CT, USA) in
the right flank as previously described [51]. Animals were
housed in specific pathogen-free facilities accredited by the
American Association for the Accreditation of Laboratory
Animal Care (AAALAC) with protocols approved by the
Animal Care and Use Committee of the Columbia Univer-
sity School of Medicine (New York, NY). Tumor dimen-
sions were measured with an electronic caliper every 2–3
days as indicated. Overall tumor volumes were calculated
as 0.5 × longest diameter × shortest diameter2. Mice were
randomized into treatment groups as indicated on day 14
when tumors reached approximately 150mm3, receiving ei-
ther Vehicle (5% DMSO in 10% 2-hydroxypropyl-β-cyclo-
dextrin) or 50mg/kg JQ1 via intraperitoneal (IP) injection
daily. Mice were sacrificed on d20 for ex vivo flow cytome-
try analysis of tumor PD-L1 and HLA-ABC expression
using the same antibodies as used for in vitro assays.
Flow Cytometry analysis of tumor infiltrating
lymphocytes (TIL)
Single cell suspensions were prepared from Myc-Cap tu-
mors via mechanical dissociation using Mouse Tumor
Dissociation Kit (Miltenyi) on program m_TDK_1 using
a gentleMACS Octo Dissociator (Miltenyi) according to
manufacturer protocol. Cells were then stained with the
following flourochrome-conjugated antibodies: Panel 1 -
CD45 BV421 (Clone 30-F11, BioLegend), CD8 BV510
(Clone 53–6.7, BioLegend), CD4 BV650 (Clone RM4–5,
BioLegend), CTLA-4 PE-TexasRed (Clone UC10-4B9,
BioLegend), PD-1 PE/Cy7 (Clone 29F.1A12, BioLegend),
TCRb AF700 (Clone H57–597, BioLegend); Panel 2 –
CTLA-4 BV421 (Clone UC10-4B9, BioLegend), PD-1
BV605 (Clone 29F.1A12, BioLegend), CD4 BV650
(Clone RM4–5, BioLegend), CD8 AF700 (Clone 53–6.7,
BioLegend). Intracellular stains were as follows: Panel 1
– CTLA-4 PE-TexasRed (Clone UC10-4B9, BioLegend),
FoxP3 FITC (Clone FJK-16 s, Invitrogen); Panel 2 –
CTLA-4 BV421 (Clone UC10-4B9, BioLegend), TNFα
FITC (Clone MP6-XT22, BD), Granzyme B APC (Clone
BG11, Invitrogen). For intracellular staining, cells were
fixed and permeabilized using fixation/permeabilization
concentrate and diluent (eBiosciences, San Diego, CA) at
room temperature for 45 min. For intracellular cytokine
staining, cells were stimulated with PMA (50 ng/ml)/
ionomycin (500 ng/ml) for 4 h in the presence of protein
transport inhibitor cocktail (eBiosciences, San Diego,
CA). Cells were analyzed using a BD FACSCelesta (Bec-
ton Dickinson, Franklin Lakes, New Jersey, USA) and
FlowJo software (Tree Star, Ashland, Oregon, USA).
Statistical methods
GraphPad Prism 6 and R (3.4.3, CRAN) were used for
statistical analysis. Quantitative data are shown as
mean ± Standard Error of the Mean (SEM) unless other-
wise stated. For all comparisons, groups were compared
to the DMSO (vehicle) treated group unless otherwise
indicated. Multiplicity adjusted P-values from one-way
ANOVA analysis was used to determine significance,
with a p < 0.05 considered significant. Family-wise sig-
nificance was set to 0.05 (95% confidence interval).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40425-019-0758-y.
Additional file 1: Table S1. List of inhibitors used to target epigenetic
modifiers. The major classes of epigenetic modulators are abbreviated
MT =methyltransferase; PAD = protein arginine deiminase; BRD =
bromodomain; HDAC = Histone deacetylase.
Additional file 2: Figure S1. Effects of BET Bromodomain Inhibition on
proliferation of DU145 and PC3 cells. A. % Cell proliferation of DU145
treated with JQ1 at indicated concentrations as measured through MTT
assay. N = 2/iteration, repeated × 3. All comparisons made to DMSO
treatment. B. % Cell proliferation of PC3 treated with JQ1 at indicated
concentrations as measured through MTT assay. N = 2/iteration, repeated
× 3. All comparisons made to DMSO treatment.
Additional file 3: Figure S2. BD2 Inhibition Downregulates PD-L1 Ex-
pression in Prostate Cancer. A. Histograms of PD-L1 expression in PC3
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cells treated with RVX208 and/or IFNγ with MFI as indicated, gated on
live cells. N = 1/iteration, repeated × 1. B. Summary flow cytometry data
for A. N = 1/iteration, repeated × 1.
Additional file 4: Figure S3. BET Bromodomain Inhibition
Downregulates PD-L1 and Augments MHC I Expression in MC38OVA. A.
Representative histograms of PD-L1 expression in MC38OVA cells treated
with JQ1 and/or IFNγ gated on live cells. B. Summary flow cytometry
data for A. N = 1 sample / iteration, repeated × 3. C. Representative histo-
grams of H2KbDb expression in MC38OVA cells treated with JQ1 and/or
IFNγ gated on live cells. D. Summary flow cytometry data for C. N = 1
sample / iteration, repeated × 3. * p < 0.05, **p < 0.01, *** p < 0.001,
****p < 0.0001. Error bars = standard deviation.
Additional file 5: Figure S4. BET Bromodomain Inhibition
Downregulates PD-L1 and Augments MHC I Expression in Myc-Cap. A.
Summary flow cytometry data of PD-L1 expression in Myc-Cap cells
treated with JQ1 and/or IFNγ, normalized to DMSO. N = 2 samples / iter-
ation, repeated × 3. B. Summary flow cytometry data of H2Kq expression
in Myc-Cap cells treated with JQ1 and/or IFNγ, normalized to DMSO. N =
2 samples / iteration, repeated × 3.
Additional file 6: Figure S5. Global effects of BET Bromodomain
Inhibition on Prostate Cancer. A. Differentially expressed genes between
DU145 cells treated as indicated. B. Top 20 upregulated and
downregulated genes between the 1uM JQ1 + IFNγ vs IFNγ treated
groups in PC3 cells. p < 0.05 for all significantly differentially expressed
genes. N = 3/group, repeated × 1.
Additional file 7: Figure S6. BET Bromodomain Inhibition
Downregulates PD-L1 and HLA-ABC in DU145 and PC3 xenograft tumors.
C. Summary of flow cytometry data for PD-L1 staining in ex-vivo DU145
and PC3 tumors, gated on Live CD45− cells. N = 6 mice / iteration, re-
peated × 2. D. Summary of flow cytometry data for HLA-ABC staining in
ex-vivo MC38OVA tumors gated on Live CD45− cells. N = 6 mice / iter-
ation, repeated × 2.
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